Status:
NOT_YET_RECRUITING
EVLA and Optimal Timing of Sclerotherapy
Lead Sponsor:
Turku University Hospital
Collaborating Sponsors:
Helsinki University Central Hospital
Oulu University Hospital
Conditions:
Venous Reflux
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
The aim of the study is to investigate the optimal timing of sclerotherapy for treatment of varicose tributaries on EVLA (endogenous laser ablation) patients.
Detailed Description
The study inclusion criteria is patients with main trunk (VSM, SSV, AASV) reflux to be treated with EVLA, suffering C2-C3 varicose disease, age 18-years and no severe co-morbidities. Patients with wr...
Eligibility Criteria
Inclusion
- Varicose disease of lower extremity caused by reflux of VSM, SSV or AASV to be treated with EVLA. Age over 18 years. Clinical symptoms C2-3.
Exclusion
- No severe comorbidities. Previous DVT.
Key Trial Info
Start Date :
March 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2030
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT04774939
Start Date
March 15 2021
End Date
March 15 2030
Last Update
March 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Turku University Hospital
Turku, Finland, 20520